WilmerHale Counsels Accent Therapeutics in $40M Series A Financing

  • 5.22.2018

On May 18, 2018, Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, announced its $40M Series A financing to establish a discovery platform and of therapeutic candidates targeting RNA-modifying proteins, a novel target space for precision cancer therapies. The Column Group, Atlas Venture and EcoR1 Capital provided the investment.

The WilmerHale team advising Accent was led by Stuart Falber and included Jenna Ventorino and Alex Civetta.

Read Accent Therapeutics' press release for more information.